LitCovid-sample-sentences  

PMC:7441788 / 15858-23287 JSONTXT 24 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T116 0-8 Sentence denotes Table 1.
T117 9-118 Sentence denotes Outcomes and advantage/limitation of chloroquine (CQ)/hydroxychloroquine (HCQ) clinical studies for COVID-19.
T118 119-200 Sentence denotes Author (Reference) Study design Patients Treatment Outcomes Advantage Limitations
T119 201-216 Sentence denotes Gao et al [48].
T120 217-446 Sentence denotes Rough and simple description Not mentioned CQ (No specific dosage was mentioned) CQ was superior to control in suppressing pneumonia deterioration, improving lung imaging, promoting viral conversion and shortening disease course.
T121 447-463 Sentence denotes Not significant.
T122 464-590 Sentence denotes No study design and the specific number of patients and controls were provided and thus the result appears to be unconvincing.
T123 591-608 Sentence denotes Borba et al [49].
T124 609-1095 Sentence denotes Randomized controlled trial High-dose CQ group: n = 40;Low-dose CQ group:n = 41 high-dose CQ (600 mg/2 times/day, for 10 day);low-dose CQ (450 mg/2 times/day for 5 days, double dose on 1st day) The mortality rate in the high-dose group was more than double that in low-dose group Double-blind study; 2 dosages of CQ for the first time in severe COVID-19 Small sample size; single-center design; Lack of a placebo control; Lack of exclusion criteria based on the QTc interval at baseline
T125 1096-1314 Sentence denotes Chen et al.[50] Randomized trial HCQ group: n = 31; control group: n = 30 HCQ (200 mg/2 times/day for 5 days) HCQ group have small improvement in body temperature and cough compered with control group Randomized trial.
T126 1315-1399 Sentence denotes Small sample size; Single-center design; Small improvement in temperature and cough.
T127 1400-1419 Sentence denotes Mahévas et al [53].
T128 1420-1638 Sentence denotes Comparative study HCQ group: n = 84; control group: n = 97 HCQ 600 mg/day for 7 days Compared with control group, a reduction of admissions to ICU or death 7 days after hospital admission was not observed in HCQ group.
T129 1639-1705 Sentence denotes Relatively larger sample size in HCQ treatment and control groups.
T130 1706-1816 Sentence denotes Nonrandomized design; In propensity score model, four possible important prognostic variables were unbalanced.
T131 1817-1833 Sentence denotes Tang et al [54].
T132 1834-1915 Sentence denotes Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80.
T133 1916-2122 Sentence denotes HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19.
T134 2123-2151 Sentence denotes Randomized controlled study.
T135 2152-2350 Sentence denotes Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased.
T136 2351-2534 Sentence denotes The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided.
T137 2535-2611 Sentence denotes The trial terminated early due to the difficulty to recruit enough patients.
T138 2612-2824 Sentence denotes Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results.
T139 2825-2844 Sentence denotes Geleris et al [55].
T140 2845-3088 Sentence denotes Observational study HCQ group: n = 811; no-HCQ group: n = 565 HCQ (600 mg/2 times on the first day, then 400 mg once a day for 4 days) No correlation between the HCQ use and significant higher or lower risk of intubation or death was observed.
T141 3089-3260 Sentence denotes Large sample size; Minimization of the unmeasured confusion and error through multivariable Cox model with inverse probability weighting according to the propensity score.
T142 3261-3370 Sentence denotes Single-center design; missing of some variables; Potential for inaccuracies in the electronic health records.
T143 3371-3385 Sentence denotes Yu et al [56].
T144 3386-3560 Sentence denotes Retrospective study HCQ group: n = 48; no-HCQ group: n = 502 HCQ (200 mg/2 times/day, for 7 to 10 days) The fatalities of HCQ group was significantly lower than no-HCQ group.
T145 3561-3689 Sentence denotes HCQ treatment was related to significantly reduced mortality in critically ill COVID-19 patients and greatly lowered IL-6 level.
T146 3690-3780 Sentence denotes Mortality was used as a measure of outcome and the study included critically ill patients.
T147 3781-3862 Sentence denotes Retrospective design of the study and the number of HCQ group patients was small.
T148 3863-4133 Sentence denotes Gautret et al.[57] Open label, nonrandom cohort study HCQ group: n = 12; HCQ＋azithromycin group: n = 6; control group: n = 12 HCQ (200 mg/3 times/day for 10 days) HCQ alone or in combination with azithromycin could effectively eliminate nasopharyngeal virus in 3–5 days.
T149 4134-4195 Sentence denotes Nasopharyngeal virus determination was used as main endpoint.
T150 4196-4345 Sentence denotes Small sample size; Six patients dropped out due to critical illness or intolerance to the drug; Lack of clinical outcomes; Limited follow-up results.
T151 4346-4365 Sentence denotes Gautret et al [58].
T152 4366-4609 Sentence denotes Observational study HCQ group: n = 80; no control HCQ, 200 mg/3 times/day for 10 days combined with azithromycin 500 mg on the 1st day, 250 mg/day afterward for 5 days The nasopharynx viral load in most patients received HCQ decreased rapidly.
T153 4610-4648 Sentence denotes Observation of nasopharynx viral load.
T154 4649-4733 Sentence denotes Observational study design and no control group; No clinical outcomes were analyzed.
T155 4734-4781 Sentence denotes Possible confounding factors were not adjusted.
T156 4782-4803 Sentence denotes Magagnoli et al [59].
T157 4804-4900 Sentence denotes Retrospective study HCQ group:n = 97HCQ＋azithromycin: n = 113No HCQ group:n = 158 Not specified.
T158 4901-5123 Sentence denotes The use of HCQ, either with or without azithromycin, didn’t reduce the risk of mechanical ventilation in patients hospitalized with COVID-19; Patients treated with HCQ alone was associated with increased overall mortality.
T159 5124-5345 Sentence denotes The study data comes from a comprehensive electronic medical record; Strictly defined covariates and outcomes; Using propensity scores adjustment for a large number of relevant confounders to make results more persuasive.
T160 5346-5539 Sentence denotes Retrospective nature of the study; The subjects included only men and most of them were black; Despite adjustments to many possible confounding factors, there may still be undiscovered factors.
T161 5540-6046 Sentence denotes Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality.
T162 6047-6129 Sentence denotes This study include a large, random sample from 25 metropolitan New York hospitals.
T163 6130-6294 Sentence denotes The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome.
T164 6295-6436 Sentence denotes Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders.
T165 6437-6516 Sentence denotes The dosing in the doses and frequencies of HCQ and azithromycin varied greatly.
T166 6517-6576 Sentence denotes The confidence intervals for some of the findings are wide.
T167 6577-7035 Sentence denotes Mehraet al[61] Multinational real-world analysis Teatment groups: n = 14,888Control group: n = 81,144 Mean daily dose: CQ 765 mg, (SD 308); HCQ 596 mg(126); CQ with a macrolide 790 mg(320); HCQ with a macrolide 597 mg(128).mean duration:CQ 6.6 days(2.4); HCQ 4.2 days(1.9);CQ with a macrolide 6.8 days(2.5); HCQ with a macrolide 4.3 days (2.0) A benefit of HCQ or CQ, when used alone or witha macrolide, on in-hospital outcomes for COVID-19 was not observed.
T168 7036-7110 Sentence denotes Large multinational real-world data and large number of study populations.
T169 7111-7429 Sentence denotes There may be potential confounders; It did not measure QT intervals and stratify the arrhythmia pattern; It did not determine whether the increased risk of death in-hospital and use of drug treatment regimens were directly related to cardiovascular risk; It did not observe the risk of the drug dose-response analysis.